Search results Search for: Search Refine your results by duration: Any Under 5 mins Under 20 mins Over 20 mins Sort by: Relevance Views Date Successful Scale Up of a High Yielding Viral Vector Suspension Platform to 500 L John Ketz, at Andelyn Biosciences, Denis Kole, at Pall Corporation and Benben Song, at Pall Corporation As gene therapies move toward commercialization, the journey to manufacture a high-quality product while achieving economies of scale and reducing fac... July 12, 2022 2:00pm Material Requirements to Support Gene Therapy Development Clare Blue, Director of Analytical Development at Biogen and James Wilkinson, VP of Sales and Customer Success at Refeyn Manufacturing processes for gene therapy products are generally low yielding compared to production processes for other biologics. The material requir... 1 month ago | 73 mins Agreeing sustainable value-based contracts with payers: myths and realities Josie Godfrey, Malcom Qualie, Heather McDonald, John Pinching Value-based contracts (VBC) are increasingly considered by companies for many types of therapies, with some suggesting that VBC will become the defaul... July 13, 2022 9:30am Cell&Gene therapy orchestration in a point-of-care production model Dell Technologies Join to learn more about a closed-loop supply chain in healthcare. Personalized treatments, like autologous cell therapies, are based on a concept th... 3 months ago | 32 mins Cell&Gene therapy orchestration in a point-of-care production model Dell Technologies Join to learn more about a closed-loop supply chain in healthcare. Personalized treatments, like autologous cell therapies, are based on a concept th... 4 months ago | 32 mins CMC Progression from Early to Late Phase... Sarah Thomas, Vice President of Quality at REGENXBIO Inc. and Joanna Zmurko, NGS specialist at PathoQuest Full Title: CMC Progression from Early to Late Phase – Practical Considerations for Gene Therapy The principles for developing traditional biologics ... 3 months ago | 88 mins Enabling Scalable & Cost-Effective Point of Care for Cell & Gene Therapies Qasim Rafiq, Xavier de Mollerat du Jeu, Sean Chang The transformative potential to change the way human disease is treated using cell and gene therapy has motivated rapid technological advancements tow... 12 months ago | 62 mins GMP Ancillary Materials for Cell & Gene Therapy Manufacturing: What to Consider Kasey Kime, Eric Roos This webinar covers regulatory requirements for GMP ancillary materials and the importance of regulatory documentation and support. Considerations for... 12 months ago | 43 mins Regulatory Strategies For Rapid Sterility Testing... Dr. Michael J. Miller, at Microbiology Consultants, LLC and Lori Daane, at bioMérieux Full Title: Regulatory Strategies For Rapid Sterility Testing of Gene and Cell Therapy Products The need to utilize rapid sterility testing is gainin... 4 months ago | 122 mins A Successful Journey to Cell Therapy Manufacturing: From R&D to Lot-Release Kasey Kime, Sean Chang, Uma Lakshmipathy Cell therapy is a transformative cancer treatment that utilizes genetically modified cells from a healthy donor or patient's own immune system to atta... 12 months ago | 45 mins Load more
